SBC Medical Group (NASDAQ:SBC) Hits New 52-Week High – What’s Next?

Shares of SBC Medical Group Holdings Incorporated (NASDAQ:SBC) hit a new 52-week high on Monday . The company traded as high as $5.09 and last traded at $5.0270, with a volume of 47270 shares trading hands. The stock had previously closed at $4.75.

Analysts Set New Price Targets

A number of equities analysts have commented on SBC shares. Wall Street Zen upgraded shares of SBC Medical Group from a “buy” rating to a “strong-buy” rating in a report on Saturday. Weiss Ratings reissued a “sell (d+)” rating on shares of SBC Medical Group in a research report on Wednesday, August 19th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $8.00 price objective on shares of SBC Medical Group in a research report on Thursday, August 13th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $8.50.

SBC Medical Group Stock Performance

The business has a 50-day moving average price of $3.66 and a 200-day moving average price of $3.53. The firm has a market capitalization of $533.26 million, a price-to-earnings ratio of 11.03 and a beta of 0.63. The company has a quick ratio of 3.27, a current ratio of 3.31 and a debt-to-equity ratio of 0.09.

SBC Medical Group (NASDAQ:SBC) last posted its quarterly earnings data on Thursday, August 13th. The company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.02). The business had revenue of $49.19 million during the quarter, compared to analyst estimates of $45.37 million. SBC Medical Group had a return on equity of 18.47% and a net margin of 27.99%. As a group, sell-side analysts forecast that SBC Medical Group Holdings Incorporated will post 0.44 earnings per share for the current year.

Institutional Investors Weigh In On SBC Medical Group

Several institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC purchased a new stake in shares of SBC Medical Group during the second quarter worth about $446,000. BlackRock Inc. purchased a new position in shares of SBC Medical Group in the 2nd quarter valued at approximately $2,846,000. Bank of America Corp DE purchased a new position in shares of SBC Medical Group in the 2nd quarter valued at approximately $35,000. Deutsche Bank AG acquired a new stake in SBC Medical Group in the 2nd quarter worth approximately $58,000. Finally, Bank of New York Mellon Corp acquired a new stake in SBC Medical Group in the 2nd quarter worth approximately $83,000. Institutional investors and hedge funds own 60.82% of the company’s stock.

SBC Medical Group Company Profile

SBC Medical Group (NASDAQ: SBC) is a Japan-based medical services and management company focused primarily on the aesthetic medicine sector. Through its affiliated medical corporations and clinic network, the company supports the operation of facilities offering cosmetic surgery, cosmetic dermatology and related elective treatments.

The company provides a range of management and operational services to affiliated clinics, including branding and marketing, staff recruitment and training, purchasing, information technology, administrative support and business consulting.